This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients (JMAD)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 8, 2009
Last updated: November 2, 2009
Last verified: November 2009
The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.

Condition Intervention Phase
Type 2 Diabetes Drug: AZD1656 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: A Randomized, Single-blind, Placebo-Controlled, Multi-centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG [ Time Frame: Blood samples taken repeatedly during 24 hours on study day sessions ]

Secondary Outcome Measures:
  • Pharmacokinetic variables (AUC, Cmax, tmax, t½, CL/F, Ae and CLR). [ Time Frame: Blood samples taken repeatedly during 24 hours on study day sessions ]
  • Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide). [ Time Frame: Blood samples taken repeatedly during 24 hours on study day sessions ]

Estimated Enrollment: 24
Study Start Date: May 2009
Study Completion Date: October 2009
Arms Assigned Interventions
Experimental: A
3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
Drug: AZD1656
Three increasing dose-steps with oral suspension, 8 days treatment
Placebo Comparator: B
Placebo oral suspension given to 3 groups (2 on placebo in each group)
Drug: Placebo
Placebo oral suspension, 8 days treatment


Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female non-childbearing potential Japanese T2DM patients, 30-75 years.
  • A body mass index (BMI) of 19 to 27 kg/m2.
  • Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment.

Exclusion Criteria:

  • Renal dysfunction GFR < 60 mL/min.
  • Systolic pressure (SBP) > 160 mmHg or diastolic pressure (DBP) > 95 mmHg
  • Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP.
  • History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00916604

Research Site
Fukuoka, Japan
Research Site
Tokyo, Japan
Sponsors and Collaborators
Study Director: Klas Malmberg, MD AstraZeneca R&D Mölndal
Principal Investigator: Takashi Eto, MD, PhD PS Clinic, Fukuoka, Japan
Principal Investigator: Mitsuyasu Hokamura, MD HONJO CLINIC II, Tokyo, Japan
  More Information

Responsible Party: Klas Malmberg, MD, PhD, Prof, Medical Science Director, AstraZeneca Pharmaceuticals Identifier: NCT00916604     History of Changes
Other Study ID Numbers: D1020C00004
Study First Received: June 8, 2009
Last Updated: November 2, 2009

Keywords provided by AstraZeneca:
Multiple ascending doses

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on July 21, 2017